upLIFT
62 evidence topics · 14 sources
Objective
Objectives stated in the ClinicalTrials.gov brief summary
Main objective in the EU Clinical Trials Information System record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-04-16” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-09” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-09” (opens the source at this quote in a new tab)
“First Posted 2025-03-18” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-28” (opens the source at this quote in a new tab)
“Recruiting” (opens the source at this quote in a new tab)
“No Results Posted” (opens the source at this quote in a new tab)
Planned number of sites and countries in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
European member states, trial dates, and recruitment status in the EU Clinical Trials Information System record
“Locations France, Netherlands” (opens the source at this quote in a new tab)
“Start of trial 10/03/2026” (opens the source at this quote in a new tab)
“Ongoing, recruitment ended” (opens the source at this quote in a new tab)
“Estimated end of trial date in EU/EEA: 09/09/2030” (opens the source at this quote in a new tab)
“Estimated global end date of the trial: 10/09/2030” (opens the source at this quote in a new tab)
Planned conduct primarily in the United States at IND clearance
Enrollment in the United States and Europe at fiscal year end 2026
Completion of enrollment and expected topline timing
Study initiation and current status in the quarterly report
Study design
Official title in the ClinicalTrials.gov record
Allocation, intervention model, and masking in the ClinicalTrials.gov record
Study periods in the ClinicalTrials.gov record
Current single-arm, open-label design described by the company
Multicenter design in the corporate presentation
Original randomized, placebo-controlled design at IND clearance
Design change agreed with the FDA in August 2025
Removal of the hypoglycemia event endpoint in the annual report
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Age and sex eligibility in the ClinicalTrials.gov record
Requirement for continuous parenteral dextrose described by the company
Treatment
Arm and intervention in the ClinicalTrials.gov record
Pivotal dosing and extension dosing frequency
Dosing described in the results release
Once-weekly administration in the corporate presentation
Study outcomes
Rationale for using glucose infusion rate reduction of at least 50% as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Primary endpoint and additional endpoints defined by the company
Responder window within the pivotal treatment phase
Functional status among additional endpoints in the corporate presentation
Glucose infusion rate as an objective endpoint measured in hospital
Expanded access data that informed the endpoint and the design revision
Basis for the streamlined design stated by the company
Design modification to improve the likelihood of demonstrating efficacy
Glucose infusion rate assessment contrasted with self-monitored measures in sunRIZE
Clinical relevance of parenteral glucose dependence in tumor hyperinsulinism (insulinoma)
“Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Success threshold of a lower 95% confidence bound above 30%
Agreement with the FDA on an adequate and well-controlled program
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment of 16 participants at study completion of enrollment
Participants included in the preliminary primary endpoint evaluation
Criterion for statistical significance of the responder proportion
Responder rate and confidence interval required for 16 participants
Description of analysis sets
Classification of the participant who entered hospice as a non-responder
Denominator of 16 enrolled participants for the significance threshold
Final statistical analysis pending after the preliminary evaluation
Results
Participant disposition
Preliminary disposition at the November 2026 data evaluation
Withdrawal of the participant with stage 4 colon cancer at the interim update
Continuation into the open-label extension at the interim update
Baseline characteristics
Tumor types of the 16 enrolled participants (insulinoma and non-islet cell tumor)
Mechanism of hypoglycemia in the enrolled participants
Tumor types of the first 8 participants at the interim update
Efficacy results
Preliminary primary endpoint result at the November 2026 data evaluation
Preliminary results subject to change before the final analysis
Preliminary interim result in the first 8 participants (June 2026)
Preliminary update of the first 8 participants to 7 responders
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Preliminary safety in the pivotal and extension phases (November 2026)
Preliminary drug-related adverse events stated in the prospectus supplement
Death due to cancer progression after withdrawal to hospice
Study limitations
Summary
- Design: upLIFT is a single-arm, open-label trial of 16 participants with no concurrent comparator, so the responder proportion is judged against a prespecified threshold (lower bound of the 95% confidence interval above 30%). The source documents word the threshold as “must exceed 30%” and as “must be ≥30%”.
- Status of the data: the results are preliminary and come from company press releases and SEC filings; no publication, congress presentation, or registry results exist. At the 13 November 2026 evaluation, 3 participants remained in the pivotal period, and the final responder proportion and its confidence interval may differ.
- Applicability: participants are adults who require IV glucose or parenteral nutrition despite standard-of-care therapies, with the primary endpoint measured in a hospital setting, and receive ersodetug as an add-on; the results describe the most severe presentation. Results by tumor type (insulinoma or non-islet cell tumor) and patient-reported quality of life have not been reported.
- One participant with stage 4 metastatic colon cancer withdrew to hospice and was counted as a non-responder; outcomes in participants with poor performance status are therefore represented by a single case.
- Registry records lag the company: ClinicalTrials.gov still lists the trial as recruiting, while the company reports enrollment complete.